# Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

> **NCT01568489** · PHASE2 · COMPLETED · sponsor: **HanAll BioPharma Co., Ltd.** · enrollment: 120 (actual)

## Conditions studied

- Mild to Moderate Atopic Dermatitis

## Interventions

- **DRUG:** HL-009 Liposomal Gel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01568489
- **Lead sponsor:** HanAll BioPharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-09
- **Primary completion:** 2013-06-11
- **Final completion:** 2013-06-11
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01568489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01568489, "Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01568489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*